Bezyl is teaming up with contract research organization Thread to provide clinical trial patients with access to the digital mental health company’s app and support systems.

In news that’ll certainly be music to many ears, a surgeon-led team in Texas was able to successfully implant what it says is the first ear to be 3D-printed using the patient’s own cells.

Back in 2020, Amgen cast aside a cardiovascular disease hopeful from Cytokinetics and pointed the spotlight at a small interfering RNA treatment it thought could make up for the lost partnership. Now, in some limited phase 2 data, the pharma is making its case.

The last time Samantha Truex was CEO of a biotech, she did something rare: She admitted defeat. Quench Bio was wrapping up after a “successful failure” and doing so with money in the bank to hand some capital back to investors.

BD said it would issue software updates for two of its products after discovering separate privacy concerns and potential hacking risks in each.

BioMarin’s commercial aspirations for its hemophilia gene therapy remain on ice after the FDA lobbed additional questions for the company to address, pushing back an expected approval submission to September.

As Altoida’s Alzheimer’s disease screening platform inches closer to FDA clearance, the company is bulking up its clinical team.

After winding down its oncology program to pivot to multiple sclerosis, TG Therapeutics has suffered a fresh setback as its lead candidate faces an additional three-month wait for an FDA decision.

RhoVac’s attempt to develop the first antigen vaccine for prostate cancer has ended in a phase 2 trial failure and forced the Swedish biotech to initiate cost cutting measures.

Could fat hold the key to finally treating Parkinson’s disease? A study by researchers at Harvard Medical School and Massachusetts General Hospital has suggested that fatty tissue could produce a source of homegrown stem cells needed to create long-sought-after regenerative treatments for a range of central nervous system disorders.